Other Diseases

Pfizer and OPKO Health: A step closer to FDA Nod for pediatric growth hormone deficiency (GHD) drug, Somatrogon Pfizer and Opko had joined hands in 2014 to develop somatrogon, a pediatric growth hormone deficiency (GHD) drug. It comprises the natural sequence of growth hormone and a copy of the C-terminal peptide (CTP) from the beta chain of human chorionic hCG at the N-terminus and two copies at the C-terminus, which helps in extending the half-life of the molecule.  The drug had already been rewarded with Orphan Drug designation by the US FDA and EU for the treatment of children and adults with growth hormone deficiency. Growth hormone deficiency (GHD) is...